The Daily Toke

March 18, 2026

Virginia's five-year wait for a legal cannabis marketplace is finally ending. After legalizing possession in 2020 but failing to establish a way for people to actually purchase it, state lawmakers last week approved legislation creating a regulated retail system expected to launch in 2027. The compromise bill represents a significant shift in how the state handles cannabis—setting up a structured market with tax revenue projected to exceed $400 million annually while maintaining strict limits on hemp-derived THC products. 💰 MONEY MOVES The retail framework could transform Virginia's cannabis economy from a shadow market into a regulated industry generating substantial state revenue while creating legal employment opportunities.

The legislative momentum extends beyond Virginia. Pennsylvania lawmakers are advancing cannabis regulation despite continued gridlock on recreational legalization, with senators amending a bill to ban most hemp THC products in alignment with a federal policy change taking effect in November. Georgia's House passed legislation to modernize its medical cannabis program with broad bipartisan support. Colorado sent Governor Jared Polis a bill allowing terminally ill patients to use medical cannabis in hospitals. Tennessee lawmakers relaunched their "Pot for Potholes" campaign for recreational legalization. Meanwhile, Ohio's controversial marijuana law overhaul under Senate Bill 56 takes effect this week—and cannabis advocates are already gathering signatures to overturn it, signaling that not all state-level cannabis policy changes have smooth sailing.

But progress faces real friction in other states. Florida's cannabis legalization measure was blocked from the 2026 ballot after the state Supreme Court rejected a campaign's appeal to restore rejected ballot signatures, effectively killing the effort. New Hampshire's House let marijuana legalization and psilocybin therapy bills die without floor votes before adjourning. Idaho voters would likely support medical marijuana legalization according to polling, yet conservative-controlled legislatures have made the ballot initiative process so difficult through geographic distribution requirements that popular measures never reach voters in the first place. 🤔 THINK ABOUT IT What does it mean when documented public support exists for a policy, but structural barriers designed by lawmakers prevent that policy from ever reaching the ballot?

Meanwhile, a major research void is creating serious problems for patients and policy credibility. A sweeping analysis published in The Lancet Psychiatry—the largest systematic review of cannabis and mental health studies in 45 years—concluded there is little to no high-quality evidence that cannabis helps anxiety, PTSD, or depression, despite these being the top reasons people use medical marijuana. The analysis examined over 50 randomized-controlled trials and found conditions like insomnia and autism had more supporting data, though even that was deemed "low quality." Jack Wilson, the Australian researcher who led the review, told NPR that "the routine use of medical cannabis products really should be rarely justified for the treatment of mental health disorders" without better evidence. The fundamental problem: cannabis has been Schedule 1 for over 50 years, which makes well-funded clinical trials extraordinarily difficult to conduct and fund. 🚀 THIS IS COOL Conditions like Tourette's syndrome and certain types of autism showed some promising data, suggesting future research could unlock legitimate therapeutic applications—but that research can't happen at scale while federal prohibition remains in place.

On the federal front, a 9th Circuit court decision created a circuit split by ruling the Dormant Commerce Clause does not apply to state cannabis markets. This could have major implications for how states can regulate cannabis trade across borders. Additionally, Senator Jeff Merkley filed a Senate amendment that would help cannabis industry workers qualify for federally backed mortgage loans by treating cannabis income the same as income from other industries—a practical recognition that the legal cannabis workforce exists and deserves financial access. President Trump previously signaled interest in loosening cannabis's Schedule 1 designation, which could fundamentally reshape the legal landscape for research and interstate commerce.

The pattern is clear: states are moving forward faster than the federal government, creating 24 different regulatory frameworks across legalized jurisdictions while research gaps widen and workers in the legal industry face federal barriers to basic financial services. Virginia's 2027 launch will add another model to the mix. Meanwhile, patients relying on cannabis for mental health conditions are doing so without high-quality evidence to guide them—a gap that persists directly because Schedule 1 classification strangles research funding. The political momentum is real. The policy mechanisms are getting built. But the federal contradiction remains: a plant legal in numerous states, generating hundreds of millions in tax revenue, is still treated as having no medical value at the federal level—making it nearly impossible to answer basic scientific questions about how it actually works.

March 18, 2026

Regulatory chaos is sweeping across America as states scramble to define, restrict, or ban intoxicating hemp-derived THC products before federal policy shifts later this year. Texas is leading the charge with an March 31 deadline that will effectively eliminate smokable hemp statewide—a move that could shutter hundreds of small businesses and devastate an industry that employs over 50,000 people and generates $10–12 billion annually. The Texas Department of State Health Services finalized rules that measure total THC content by accounting for THCA conversion, a definitional change that manufacturers say makes compliant products nearly impossible to produce. 💰 MONEY MOVES Mark Bordas, executive director of the Texas Hemp Business Council, warned that store closures are imminent: "You're talking about major market disruption to an industry that generates over $10-12 billion a year." Some operators expect 60–70% revenue declines within three weeks; others say they'll be forced to close entirely.

South Carolina presents a different picture—internal Republican division has stalled a decision. Last week, GOP senators narrowly voted against an outright ban on intoxicating THC consumables, choosing instead to debate how to regulate the growing market. Senate Majority Leader Shane Massey acknowledged the split: "This went off the rails over there [the House]. My hope is that if we can come to a consensus on a good regulatory scheme, and we demonstrate some leadership in that regard, my hope is that the House would recognize that and then would act on it accordingly." Seven bills are now circulating through the statehouse as the hemp industry describes the situation as an "absolute roller coaster," with enforcement ramping up despite legal ambiguity. Pennsylvania took yet another approach, amending its cannabis regulation bill to ban most hemp THC products in alignment with the pending federal policy shift expected in November. Senator Dan Laughlin framed the move as closing loopholes created by the 2018 Farm Bill: "As the federal government updates its definition of hemp, Pennsylvania needs to make sure our laws remain consistent and enforceable."

Rhode Island's Cannabis Control Commission is recommending a different strategy—banning THC drinks specifically from venues with liquor licenses, citing public health concerns. Over 100 bars and restaurants obtained licenses between August 2024 and July 2025 before regulators hit the brakes. Farouk Rajab, president of the Rhode Island Hospitality Association, accused regulators of targeting his industry: "I think decisions are already made even before the listening sessions. This is targeting an industry, that's all." Carla Aveledo, chief of policy for the commission, countered that the proposal applies uniform safety standards: "All retailers selling intoxicating hemp products should be held to similar high safety standards as cannabis retailers." The tension reflects a broader national pattern—regulators are playing catch-up with a marketplace that evolved faster than policy frameworks, and industry stakeholders are caught between legitimate regulatory concerns and what some see as selective enforcement.

Congressional researchers just released an updated analysis on marijuana rescheduling and the hemp THC ban, notably removing language from an earlier version that said it was "likely" federal officials would move cannabis from Schedule I to Schedule III. The report now says DOJ "may" move forward if Congress takes no action—a subtle but significant shift in certainty. Even if rescheduling happens, the Congressional Research Service notes it would not bring state-legal medical or recreational marijuana into federal compliance without additional legislation. That legal limbo sets the backdrop for state-level chaos: some states ban hemp products preemptively, others try to regulate them, and a few maintain the status quo while waiting for federal clarity.

🤔 THINK ABOUT IT The hemp THC industry was born from a loophole in the 2018 Farm Bill—legal hemp products containing less than 0.3% Delta-9 THC, but manufactured with high THCA that converts to THC when consumed. Regulators and lawmakers now disagree on whether to close that loophole through bans or regulation. But here's the inconsistency: hemp-derived THC products have never killed anyone. Alcohol kills approximately 95,000 Americans per year. Prescription opioids kill 16,000+. Yet the federal response is to potentially eliminate a zero-death product while those legal substances remain not just legal but heavily taxed and advertised. Whether states choose regulation or prohibition, the underlying question remains unanswered: what problem, exactly, are these bans solving, and at what cost to small business owners, patients seeking alternatives, and veterans using THC for PTSD and chronic pain?

March 18, 2026

# THC in Science: Major Review Finds Mental Health Claims Lack Evidence

A sweeping analysis of 54 clinical trials spanning 45 years has dealt a significant blow to the widespread use of medicinal cannabis for psychiatric conditions. Researchers at the University of Sydney, led by Dr. Jack Wilson, examined data from nearly 2,500 patients and found virtually no high-quality evidence that cannabis treats anxiety, depression, or post-traumatic stress disorder—the three conditions patients most frequently cite when seeking medical cannabis. The findings, published in The Lancet Psychiatry in March 2026, represent the largest systematic review of its kind and underscore a troubling reality: public embrace of cannabis for mental health has dramatically outpaced scientific validation.

The research team cast a wide net, evaluating randomized controlled trials—the gold standard for medical evidence—that tested various cannabinoids, formulations, and dosages across multiple psychiatric and substance-use disorders. What they found was stark: zero trials were available to assess cannabis for depression alone, and conditions like anxiety and PTSD showed no meaningful benefit over placebo. 🚀 THIS IS COOL The analysis did identify limited promise for cannabis withdrawal symptoms, insomnia, autism spectrum traits, and Tourette syndrome, though even those findings were deemed "low quality" by the investigators. "We clearly need to do more research on cannabis medicines," Wilson told NPR. "In the absence of evidence at this time, the routine use of medical cannabis products really should be rarely justified for the treatment of mental health disorders."

The gap between prescription and evidence is staggering. In Australia alone, over 700,000 people have used medicinal cannabis in the past year, with prescription approvals exceeding one million and sales quadrupling since 2022. About a quarter of adults aged 16–65 in the US and Canada report using medicinal cannabis, with roughly half using it specifically for mental health. Yet the majority of products prescribed in Australia aren't even registered with the Therapeutic Goods Administration, meaning they've never undergone rigorous testing. 💰 MONEY MOVES This disconnect has created a market boom—sales are climbing sharply—even as the scientific foundation supporting these prescriptions crumbles. States across America have authorized cannabis for depression, anxiety, and PTSD despite this new evidence calling efficacy into serious question.

One bright spot emerged from the research: cannabis-based medicines showed promise for cannabis use disorder itself, likely because the CBD-THC combinations reduce cravings and lower weekly consumption. Paradoxically, using cannabis to treat cannabis dependence may work similarly to how methadone treats opioid addiction. Additionally, a separate study published in the Journal of Pain Research found that 🚀 THIS IS COOL CBD-dominant full-spectrum extracts significantly outperformed pure THC in older adults with chronic pain, delivering stronger pain relief with fewer side effects—85.7% of CBD patients achieved meaningful improvement versus only 21.9% of the THC group. This suggests that cannabinoid profile and formulation matter considerably, and that not all cannabis is created equal.

The research also flagged safety concerns. Among all 54 trials reviewed, 44% carried high risk for bias and only 18% had low risk. Patients on cannabinoids reported higher rates of adverse events overall, and notably, cocaine users who took cannabinoids experienced increased cravings compared to placebo. 🤔 THINK ABOUT IT Millions of people are self-medicating with unproven products for conditions like depression and anxiety, while the Schedule I classification—in place for over 50 years despite the Shafer Commission's 1970 recommendation for decriminalization—continues to obstruct the large, well-funded trials necessary to either validate or disprove these uses. Wilson cautioned that "routine use of medicinal cannabis could be doing more harm than good by worsening mental health outcomes, for example a greater risk of psychotic symptoms and developing cannabis use disorder, and delaying the use of more effective treatments." Until rigorous evidence emerges, the message is clear: cannabis for psychiatric illness isn't justified by current science.

March 18, 2026

Texas hemp businesses are bracing for significant disruption as new state regulations take effect March 31, tightening restrictions on THC and THCA—a compound that converts to delta-9 THC when heated. The Texas Department of State Health Services finalized rules that will limit consumable hemp products to those containing 0.3% delta-9 THC or less, with lab testing required and results submitted to the department upon request. The regulations also mandate age verification for all purchases, with products sold only to adults 21 and older with valid government-issued identification. These rules follow Governor Greg Abbott's executive order last fall directing statewide hemp product regulation, and they represent a dramatic shift for an industry that has flourished in Texas.

💰 MONEY MOVES The economic stakes are substantial. A 2023 economic impact report estimated Texas's hemp industry generates $22.4 billion in economic activity, supports more than 50,000 jobs, and contributes $1.6 billion in wages annually. Business owners across the state are warning that the new THCA inclusion could eliminate a significant portion of their inventory and revenue overnight. Estella Castro, owner of Austinite Cannabis Company in Austin, says the restrictions could force her to stop selling popular smokable hemp flower entirely. "To take away the flower and what we've been accustomed to and what our patients and customers have been using, that was kind of heartbreaking," Castro said. She's already exploring a pivot toward merchandise, jewelry, and coffee just to remain solvent, though she acknowledges the long-term sustainability of her business remains uncertain.

The timing creates immediate pressure for retailers and manufacturers across San Antonio, Austin, Galveston County, and beyond. State law already banned the manufacturing of consumable hemp products for smoking—a restriction the Texas Supreme Court upheld in 2022—but a lower court injunction has allowed distribution and retail sales to continue. The new rules, however, explicitly count THCA toward total THC limits, effectively making most smokable products illegal by default since they exceed the 0.3% threshold once THCA is factored in. Businesses now face inventory write-offs and disrupted supply chains with less than two weeks to comply.

🤔 THINK ABOUT IT Consumers currently using legal THC products for PTSD, chronic pain, anxiety, and as alternatives to prescription medications will suddenly face either an unregulated market or no market at all. Many of these users are working professionals, volunteers, and community members—the same demographic that might enjoy a beer after work. The difference is one product will become illegal, while the other remains on every grocery store shelf. So what does "safety-based regulation" actually look like when applied selectively to products with zero overdose deaths while maintaining full legal status for products responsible for tens of thousands of annual deaths?